arrow
D

Dale W. Garsed

Peter MacCallum Cancer Centre
H指数:43
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rethinking ovarian cancer III: the past decade and future directions

重新思考卵巢癌III:过去十年及未来方向

2026-04-130
PRE
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer
2025-02-120
OAAI
Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival

输卵管卵巢高级别浆液性癌患者结局的临床与分子预测因子及特殊生存情况

2024-09-010
PRE
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

同时RB1丢失和BRCA缺乏可预测输卵管卵巢高级别浆液性癌的免疫反应增强和长期生存

2024-06-050
OAAI
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities (vol 8, 68, 2024)

富集HGSOC肿瘤上皮的蛋白质基因组分析确定预后特征和治疗弱点 (vol 8,68,2024)

2024-05-060
OAAI
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

富集HGSOC肿瘤上皮的蛋白质基因组分析确定预后特征和治疗脆弱性

2024-03-132
OAAI
Proteogenomic analysis of enriched tumor epithelium identifies prognostic signatures and an increased dependency of homologous recombination proficient cells on bmi1 in high grade serous ovarian cancer
2024-03-040
PRE
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

微管抑制剂eribulin在铂耐药和难治性高级浆液性卵巢癌患者来源的异种移植模型中显示出疗效

2023-11-221
OAAI
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
2023-09-010
PRE
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
2023-06-203
OAAI
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

同源重组缺陷型终末期高级别浆液性卵巢癌的多组学分析

2023-02-2728
PRE
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2023-02-150
OA
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
2022-12-0135
OA
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

ESMO关于卵巢癌中同源重组缺陷和PARP抑制剂益处的预测性生物标志物测试的建议

2020-12-01271
OAAI
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

使用全基因组测序对2,658种人类癌症中的色素病进行综合分析

2020-02-05292
OAAI
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

癌症LncRNA普查揭示了长非编码rna在肿瘤发生中的深度功能保守性的证据

2020-02-05150
OAAI